lifemd semaglutide and the 503A Compounding Pathway Compounded Semaglutide (GLP-1)

MAB: Investigation, Software, Validation, Writing review and editing

When that popped up I honestly thought it was a joke or a skit, but then I looked and it said it was sponsored

Several polyphenols exert anti-psoriatic effects by modulating this pathway

Data were analysed by mixed linear model analysis followed by post hoc analysis of estimated marginal means, as described in the statistics section above

The FDA states that compounded drugs are not FDA-approved and that compounded drugs and generic drugs are not the same, since a generic must establish therapeutic equivalence under section 505(j)

Given that obesity in adolescence is already associated with an increased risk of depression and suicidal ideation, and considering the rise in GLP-1 receptor agonist prescriptions since FDA approval in 2020, it was crucial to investigate whether this treatment impacts psychiatric outcomes